Embecta Corp. (EMBC) AI Stock Analysis

Embecta Corp. is a medical device company headquartered in Parsippany, New Jersey, specializing in solutions to enhance the health and quality of life for people managing diabetes. In operation since 1924, its core portfolio includes essential diabetes management tools such as pen needles, syringes, and safety devices aimed at improving safety, comfort, and precision in insulin administration. Embecta also integrates digital applications into its products to support patient monitoring. The company sells its medical devices through an established network of wholesalers and distributors across the United States and internationally.

Between FY2021 and FY2025, revenue contracted from $1.17B to $1.08B, reflecting a 5-year revenue CAGR of -0.1%. Gross margin narrowed from 68.7% in FY2021 to 62.9% in FY2025, while operating margin shifted from 42.2% down to 30.5%. Net income was $95.4M in FY2025, producing EPS of $2.97 and a net margin of 8.8%, compared to $414.8M in FY2021. For the trailing twelve months, revenue totaled $1.02B with EPS of $1.47. In the quarter ended June 30, 2026, quarterly revenue fell 8.1% year-over-year, and quarterly earnings decreased 53.7% year-over-year.

As of June 30, 2026, Embecta held $214.7M in cash and short-term investments against total debt of $1.50B, leading to net debt of $1.29B. The company operates with negative shareholders' equity of -$612.7M and total assets of $1.27B, while maintaining a current ratio of 1.68. Free cash flow stood at $182.4M in FY2025, up from operating cash flow of $191.7M and capital expenditures of $9.3M. In FY2025, Embecta returned capital through $35.0M in dividends paid and $5.7M in share buybacks.

Embecta trades at a trailing P/E of 4.3x, an EV/EBITDA of 6.0x, and a price-to-sales multiple of 0.3x. In comparison, the median of its US-listed Healthcare peers features a trailing P/E of 24.6x, an EV/EBITDA of 12.0x, and a price-to-sales ratio of 4.1x. The company's enterprise value is $1.59B versus a market cap of $355.3M. Over the past year, EMBC stock has declined 52.7%, while the S&P 500 (SPY) gained 16.8%.

Embecta pays a quarterly dividend with an annual forward payout of $0.04 per share, translating to a dividend yield of 0.64%. The company has paid dividends for 5 consecutive years. Its payout ratio is 15.7%, and its last ex-dividend date occurred on August 27, 2026.

Wall Street coverage includes 3 Hold ratings and 1 Sell rating, with zero Buy or Strong Buy recommendations. The mean price target is $4.00, implying a 36.2% decline from the last close of $6.27. For the fiscal year ending September 30, 2026, consensus estimates project revenue of $1.02B and EPS of $1.83, a projected EPS decline of 37.8%. Embecta beat EPS expectations in 3 of the last 4 quarters, with its next earnings release scheduled for November 24, 2026.

This page is an AI-written research summary of Embecta Corp. (EMBC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EMBC income statement, EMBC balance sheet, EMBC key metrics, EMBC analyst forecast, EMBC chart. See the EMBC stock overview for the latest quote and news.